tetano
Editor, Senior Moderator
Sci Rep. 2019 Feb 21;9(1):2432. doi: 10.1038/s41598-018-38105-1.
[h=1]Molecular evolution of influenza B virus during 2011-2017 in Chaoyang, Beijing, suggesting the free influenza vaccine policy.[/h] Lei N[SUP]1,[/SUP][SUP]2[/SUP], Wang HB[SUP]1[/SUP], Zhang YS[SUP]1[/SUP], Zhao JH[SUP]1[/SUP], Zhong Y[SUP]1[/SUP], Wang YJ[SUP]1[/SUP], Huang LY[SUP]1[/SUP], Ma JX[SUP]1[/SUP], Sun Q[SUP]2,[/SUP][SUP]3[/SUP], Yang L[SUP]2[/SUP], Shu YL[SUP]2,[/SUP][SUP]3[/SUP], Li SM[SUP]4[/SUP], Sun LL[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Two influenza B virus lineages, B/Victoria and B/Yamagata, are co-circulating in human population. While the two lineages are serologically distinct and TIV only contain one lineage. It is important to investigate the epidemiological and evolutionary dynamics of two influenza B virus lineages in Beijing after the free influenza vaccine policy from 2007. Here, we collected the nasopharyngeal swabs of 12657 outpatients of influenza-like illness and subtyped by real-time RT-PCR during 2011-2017. The HA and NA genes of influenza B were fully sequenced. The prevalence is the highest in the 6-17 years old group among people infected with influenza B. Yamagata-lineage virus evolved to two inter-clade from 2011-2014 to 2014-2017. The amino acids substitutions of HA1 region were R279K in strains of 2011-2014 and L173Q, M252V in strains of 2014-2017. Substitutions L58P, I146V were observed in HA1 region of Victoria-lineage virus in 2011-2012 and I117V, N129D were showed in 2015-2017. Phylogenetic analysis of NA showed Yamagata-Victoria inter-lineage reassortant occurred in 2013-2014. Influenza B mainly infect the school-aged children in Beijing and the free influenza vaccine inoculation does not seem to block school-age children from infection with influenza B. The antigen characteristics of circulating influenza B were different to the recommended vaccine strains. We concluded that the Victoria-lineage vaccine strain should been changed and the free influenza vaccine should be revalued.
PMID: 30792414 DOI: 10.1038/s41598-018-38105-1
Free full text
[h=1]Molecular evolution of influenza B virus during 2011-2017 in Chaoyang, Beijing, suggesting the free influenza vaccine policy.[/h] Lei N[SUP]1,[/SUP][SUP]2[/SUP], Wang HB[SUP]1[/SUP], Zhang YS[SUP]1[/SUP], Zhao JH[SUP]1[/SUP], Zhong Y[SUP]1[/SUP], Wang YJ[SUP]1[/SUP], Huang LY[SUP]1[/SUP], Ma JX[SUP]1[/SUP], Sun Q[SUP]2,[/SUP][SUP]3[/SUP], Yang L[SUP]2[/SUP], Shu YL[SUP]2,[/SUP][SUP]3[/SUP], Li SM[SUP]4[/SUP], Sun LL[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Two influenza B virus lineages, B/Victoria and B/Yamagata, are co-circulating in human population. While the two lineages are serologically distinct and TIV only contain one lineage. It is important to investigate the epidemiological and evolutionary dynamics of two influenza B virus lineages in Beijing after the free influenza vaccine policy from 2007. Here, we collected the nasopharyngeal swabs of 12657 outpatients of influenza-like illness and subtyped by real-time RT-PCR during 2011-2017. The HA and NA genes of influenza B were fully sequenced. The prevalence is the highest in the 6-17 years old group among people infected with influenza B. Yamagata-lineage virus evolved to two inter-clade from 2011-2014 to 2014-2017. The amino acids substitutions of HA1 region were R279K in strains of 2011-2014 and L173Q, M252V in strains of 2014-2017. Substitutions L58P, I146V were observed in HA1 region of Victoria-lineage virus in 2011-2012 and I117V, N129D were showed in 2015-2017. Phylogenetic analysis of NA showed Yamagata-Victoria inter-lineage reassortant occurred in 2013-2014. Influenza B mainly infect the school-aged children in Beijing and the free influenza vaccine inoculation does not seem to block school-age children from infection with influenza B. The antigen characteristics of circulating influenza B were different to the recommended vaccine strains. We concluded that the Victoria-lineage vaccine strain should been changed and the free influenza vaccine should be revalued.
PMID: 30792414 DOI: 10.1038/s41598-018-38105-1
Free full text